| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00528008 Details | 2012-11-09 Interventional | 3 | 268 | Chlorhexidine Chlorhexidine g… Povidone Povidone-Iodine Communicable Di… Infections Wound Infection Wounds and Inju… | Study was stopped following interim analysis. - | |||
| NCT00795587 2008-004979-21 Details | 2012-11-08 Interventional | 4 | 3 | Mannitol Brain Injuries Brain Injuries,… Hypertension Intracranial Hy… Traumatic Brain… | evolution of patient's care allows no more recruitment - | |||
| NCT01604863 Details | 2012-11-01 Interventional | 1 | - | Carboplatin Docetaxel Etoposide Paclitaxel Neoplasms Cancer | Study suspended prior to enrollment - | |||
| NCT00656422 Details | 2012-11-01 Interventional | 3 | 66 | Insulin Insulin Detemir Insulin, Globin… Diabetes Mellit… Diabetes Mellit… Weight Gain Diabetes Obesity | - - | |||
| NCT00714376 Details | 2012-10-31 Interventional | 2 | 6 | Docetaxel Prostatic Neopl… Prostate Cancer | Prematurely terminated due to financial considerations - | |||
| NCT00698789 Details | 2012-10-30 Interventional | 2 | 48 | Metformin Diabetes Mellit… Type 2 Diabetes | Study ended after diabetes development plan review. . - | |||
| NCT01151137 2010-019791-73 Details | 2012-10-26 Interventional | 3 | [1 Refs] | 3236 | Dronedarone Atrial Fibrilla… | The study was stopped because of safety concerns Given that the study was prematurely discontinued after 3236 patients were randomized (30% of the initial planned number), p-values were provided for information without any adjustment for multiplicity. | ||
| NCT00741611 Details | 2012-10-26 Interventional | 3 | 44 | Anti-Arrhythmia… Atrial Fibrilla… Paroxysmal Atri… | Business reasons Due to the study's early termination and enrollment of only 7 randomized patients, predefined study endpoints were not evaluable. Treated patients were followed through 12 months postprocedure and data were summarized where possible. | |||
| NCT01202058 Details | 2012-10-25 Interventional | 3 | 156 | Everolimus Sirolimus Coronary Artery… Coronary Diseas… Myocardial Isch… Atherosclerotic… | The NEVO™ stent will not be commercialized. Cordis decided to close the study after 1 years.
This decision took the absence of safety signals into account. - | |||
| NCT00714883 Details | 2012-10-25 Interventional | 2 | 3 | Sirolimus Coronary Diseas… | The NEVO™ stent will not be commercialized. Cordis decided to close the study after 3 years.
This decision took the absence of safety signals into account. - | |||
| NCT00211562 Details | 2012-10-24 Interventional | 3 | 20 | Olanzapine Vitamin E Schizophrenia | - - | |||
| NCT01244269 Details | 2012-10-22 Interventional | 4 | 6 | Methylphenidate Parkinson Disea… Parkinson's Dis… | Inadequate enrolment, protocol too challenging for participants, lack of observable benefit
after analysis of 6 patients. - | |||
| NCT00503971 Details | 2012-10-22 Interventional | 1/2 | 50 | Erlotinib Hydro… Vorinostat Carcinoma, Non-… Lung Neoplasms Non-small Cell … | - - | |||
| NCT00387010 Details | 2012-10-22 Interventional | 3 | [1 Refs] | 218 | Fentanyl Breakthrough Pa… Chronic Pain Pain | The sponsor felt enough information was available for the exploratory assessment of the effect
of treatment with FBT on pain anxiety This study was terminated early. Additional research is recommended to develop a valid measure of anxiety, specifically related to breakthrough pain. | ||
| NCT00206765 Details | 2012-10-22 Interventional | 2 | - | Paroxetine Risperidone Depressive Diso… Depressive Diso… Panic Disorder Major Depressiv… | - - | |||
| NCT00555321 Details | 2012-10-18 Interventional | 2 | 260 | Abatacept Basiliximab Mycophenolic Ac… Tacrolimus Immunosuppressi… | - - | |||
| NCT00313261 Details | 2012-10-17 Interventional | 2 | - | Clevudine Hepatitis Hepatitis B | - - | |||
| NCT00121953 Details | 2012-10-17 Interventional | 2/3 | 0 | Rosiglitazone Endometriosis | Due to the recent meta-analysis about CV adverse effects. - | |||
| NCT00115661 Details | 2012-10-17 Interventional | 2 | - | Rosiglitazone Endometriosis | Due to the meta-analysis about CV adverse effects of rosiglitazone. - | |||
| NCT01352039 Details | 2012-10-16 Interventional | 3 | 544 | Calcium heparin Heparin Fractures, Bone Hip Fractures Hip Fracture Su… | - - |